Repligen Q4 revenue $168M; FY2024 $634M; guides FY2025 8-12% growth

REPLIGEN CORP

2024-FY EPS reported -$0.46 revenue$634,439,000

Q4 revenue $168M, flat YoY; FY2024 revenue $634M vs $632M.
GAAP net loss $34M ($0.60 loss per share); adjusted EPS $0.44 vs $0.48.
Orders outpaced sales by 6% in Q4; sequential revenue up 8%.
FY2025 guidance: revenue $685-710M (8-12% reported growth, 10-14% ex-COVID).
Closed acquisition of Tantti Laboratory; launched AVIPure dsRNA resin for mRNA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.